Directors buying at BELLUS Health (BLU)

Directors buying at BELLUS Health (T:BLU)

Franklin Milan Berger, a Director, acquired 177,777 Common Shares on a direct ownership basis at a price of US$2.250 through a prospectus or prospectus exempt offering on October 22nd, 2020. This represents a $525,678 investment into the company's shares and an account share holdings change of 34.1%.

In addition, Francesco Bellini, a Director, acquired 100,000 Common Shares on a direct ownership basis. This represents a $295,695 investment into the company's shares and an account share holdings change of 23.7%.

BELLUS Health is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer's disease.